PIQRAY |
NVP-BYL719 |
BYL-719 |
ALPELISIB |
BYL719 |
BYL 719 |
chembl:CHEMBL2396661 |
chemidplus:1217486-61-7 |
pubchem.compound:56649450 |
Pharmaceutical Developer | Novartis |
Source Reported Drug Name(s) | BYL719 |
Drug Class | PI3K/mTOR dual Inhibitor |
Drug Class | Kinase Inhibitors |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Categories | antineoplastic agents |
Drug Categories | bcrp/abcg2 substrates |
Drug Categories | breast cancer resistance protein inhibitors |
Drug Categories | breast neoplasms |
Drug Categories | cytochrome p-450 cyp2b6 inducers |
Drug Categories | cytochrome p-450 cyp2b6 inducers (moderate) |
Drug Categories | cytochrome p-450 cyp2c19 inhibitors |
Drug Categories | cytochrome p-450 cyp2c19 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c9 inducers |
Drug Categories | cytochrome p-450 cyp2c9 inducers (moderate) |
Drug Categories | cytochrome p-450 cyp2c9 inducers (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a inducers |
Drug Categories | cytochrome p-450 cyp3a inhibitors |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inducers |
Drug Categories | cytochrome p-450 cyp3a4 inducers (weak) |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | phosphatidylinositol 3-kinases, antagonists & inhibitors |
Drug Categories | sulfur compounds |
inhibitor (inhibitory) |
Response Type | no benefit |
combination therapy | Alpelisib + WEHI-539 |
Approval Status | Preclinical - Cell line xenograft |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
n/a |
combination therapy | BYL719 + MEK162 |
Indication/Tumor Type | ovarian cancer |
Response Type | predicted – sensitive |
n/a |
combination therapy | BGJ398 + BYL719 |
Indication/Tumor Type | transitional cell carcinoma |
Response Type | predicted – sensitive |
inhibitor (inhibitory) |
Reported Cancer Type | Lung |
ALPELISIB | DrugBank Drug Name |
1217486-61-7 | CAS Number |
Piqray | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
BYL719 | Development Name |
Drug Class | Kinase Inhibitors |
BYL719 | PubChem Drug Name |
56649450 | PubChem Drug ID |
BYL719 | Drug Trade Name |
Drug Class | PI3K/mTOR dual Inhibitor |
Source Reported Drug Name(s) | BYL719 |
Pharmaceutical Developer | Novartis |
ALPELISIB | GuideToPharmacology Ligand Name |
D0W7HE | TTD Drug ID |